Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).
Anas Younes
Consultant or Advisory Role - Pharmacyclics (U)
Honoraria - Pharmacyclics
Research Funding - Janssen; Pharmacyclics
Ian Flinn
Consultant or Advisory Role - Janssen (U)
Research Funding - Janssen; Pharmacyclics
Jesus G. Berdeja
Research Funding - Janssen
Jonathan W. Friedberg
Consultant or Advisory Role - Emergent BioSolutions (U); Lilly (U)
Sara Alberti
No relevant relationships to disclose
Catherine Thieblemont
Consultant or Advisory Role - Roche (U); Takeda (U)
Franck Morschhauser
No relevant relationships to disclose
Peter Hellemans
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Brett Hall
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Johan Smit
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Donna Skee
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Ronald de Vries
Employment or Leadership Position - Janssen Research & Development
Marija Todorovic
Employment or Leadership Position - Janssen Research & Development
Imran Khan
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Nele Fourneau
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Yasuhiro Oki
No relevant relationships to disclose